'No Future Without New Drugs': Yuhan CSO On Open Innovation Strategy

TPD, RNA, Cell/Gene Therapies All In Sights

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.

open innovation
Each Development Stage A 'Fight Against Success Rates' Yuhan Says • Source: Shutterstock

For Yuhan Corporation, the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been at the center of this era.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia